Osteoporosis treatment following hip fracture: How rates vary by service

Southern Medical Journal

Volumn 103, Issue 10, 2010, Pages 977-981

  Gregory, Patricia C ^a   Lam, Diana ^b   Howell, Paul ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Guidelines adherence; Hip fracture; Osteoporosis; Rehabilitation

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; HORMONE; VITAMIN D;

AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FRAGILITY FRACTURE; HIP FRACTURE; HORMONAL THERAPY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OCCUPATIONAL THERAPY; OSTEOPOROSIS; PHYSIOTHERAPY; REHABILITATION CARE; RETROSPECTIVE STUDY; SURVIVAL; UNIVERSITY HOSPITAL; HOSPITAL DEPARTMENT; ORTHOPEDICS; STATISTICAL MODEL; STATISTICS;

ACADEMIC MEDICAL CENTERS; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; FEMALE; HIP FRACTURES; HOSPITAL DEPARTMENTS; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; ORTHOPEDICS; OSTEOPOROSIS; PHYSICAL THERAPY DEPARTMENT, HOSPITAL; RETROSPECTIVE STUDIES; SURGERY DEPARTMENT, HOSPITAL;

EID: 77958118917     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181ebe96c     Document Type: Article

References (24)

1. Available at: http://www.nof.org/professionals/Clinicians-Guide.htm.
2. NIH Consensus Development Program. Osteoporosis Prevention, Diagnosis, and Therapy. Bethesda, MD, National Institutes of Health, 2000. Available at: http://consensus.nih.gov/2000/2000Osteoporosis11html.htm. Accessed January 6, 2010.
3. World Health Organization. WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level. Geneva, World Health Organization, 2007. [See comment in Intro: World Health Organization. Assessment of osteoporotic fracture risk and its role in screening for postmenopausal osteoporosis. WHO Technical report series no. 843. Geneva: World Health Organization 1994.]
4. Qaseem A, Snow V, Shekelle P, et al; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;149:404-415.
5. Lüthje P, Nurmi-Lüthje I, Kaukonen JP, et al. Undertreatment of osteoporosis following hip fracture in the elderly. Arch Gerontol Geriatr 2009;49:153-157.
6. Gallagher TC, Geling O, Comite F. Missed opportunities for prevention of osteoporotic fracture. Arch Int Med 2002;162:450-456.
7. Andrade SE, Majumdar SR, Chan KA, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 2003;163:2052-2057.
8. Byszewski AM, Cranney A, Man-Son-Hing M, et al. Evaluation of in-hospital management of fracture risk in older patients: a chart review study of tertiary prevention. Arch Gerontol Geriatr 2006;42:319-328.
9. Cree MW, Juby AG, Carriere KC. Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporosis Int 2003;14:722-727.
10. Juby AG, De Geus-Wenceslau CM. Evaluation of osteoporosis treatment in seniors after hip fracture. Osteoporos Int 2002;13:205-210.
11. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-340.
12. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-1541.
13. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357:1799-1809.
14. Dirschl DR, Piedrahita L, Henderson RC. Bone mineral density 6 years after a hip fracture: a prospective, longitudinal study. Bone 2000;26:95-98.
15. Magaziner J, Hawkes W, Hebel JR, et al. Recovery from hip fracture in eight areas offunction. J Gerontol A Biol Sci Med Sci 2000;55:M498-M507.
16. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-1301.
17. Morris CD, Einhorn TA. Bisphosphonates in orthopaedic surgery. J Bone Joint Surg Am 2005;87:1609-1618.
18. Kiebzak GM, Moore NL, Margolis S, et al. Vitamin D status of patients admitted to a hospital rehabilitation unit: relationship to function and progress. Am J Phys Med Rehabil 2007;86:435-445.
19. Islam S, Liu Q, Chines A, Helzner E. Trend in incidence of osteoporosisrelated fractures among 40- to 69-year-old women: analysis of a large insurance claims database, 2000-2005. Menopause 2009;16:77-83.
20. Adolphson P, Abbaszadegan H, Bodén H, et al. Clodronate increases mineralization of callus after Colles' fracture: a randomized, doubleblind, placebo-controlled, prospective trial in 32 patients. Acta Orthop Scand 2000;71:195-200.
21. Streeten EA, Mohamed A, Gandhi A, et al. The inpatient consultation approach to osteoporosis treatment in patients with a fracture. Is automatic consultation needed? J Bone Joint Surg Am 2006;88:1968-1974.
22. Harrington JT, Barash HL, Day S, et al. Redesigning the care offragility fracture patients to improve osteoporosis management: a health care improvement project. Arthritis Rheum 2005;53:198-204.
23. Kaufman JD, Bolander ME, Bunta AD, et al. Barriers and solutions to osteoporosis care in patients with a hip fracture. J Bone Joint Surg Am 2003;85:1837-1843.
24. Feldstein AC, Nichols G, Orwoll E, et al. The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int 2005;16:953-962.